SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?


To: Sergio H who wrote (5819)6/10/1998 10:01:00 PM
From: Magnatizer  Read Replies (1) | Respond to of 29382
 
Amigos y amigas

interesting synopsis of the Gorilla game book. Part one

For an enhanced HTML version of the Money Daily,
visit moneydaily.com.

Thursday, June 11, 1998

The rules of the gorilla game

Money's Duff McDonald interviews Tom Kippola, co-
author of a new high-tech investing handbook

If you read the business section of any major
newspaper, it seems like the only news that matters
these days is what is happening to Intel, Microsoft or
Dell Computer. It's no surprise: big money is on the
line, for the corporations and their investors.

MONEY writer Duff McDonald sat down with high-tech
market strategist Tom Kippola, co-author of The
Gorilla Game: An Investor's Guide to Picking Winners
in High Technology, to find out what makes a
"gorilla," Kippola's term for a winning technology
company.

MONEY.COM: This was a team effort. Who wrote The
Gorilla Game?

KIPPOLA: There are three authors. Geoff Moore and
myself are partners of the Chasm Group, which is a
Silicon Valley based high-tech market strategy firm
that offers strategy consulting services to primarily
computing and communications companies. Our third
author is Paul Johnson, who is the network analyst at
BankAmerica Robertson Stevens.

MONEY.COM: One of the interesting things about this
book, obviously, is the terminology you guys used --
including the title. What is the Gorilla Game?

KIPPOLA: The Gorilla Game is a type of growth
investing that's focused very narrowly in the high-
tech markets and on very specific kinds of technology
companies. We look for companies involved in spaces
that have not undergone hyper-growth but will undergo
hyper-growth. And when they do, they will play out so
that there will be a dominant player in that space,
which we call the gorilla. And the gorilla,
generally, gains its dominance because it has a
proprietary architecture with high switching costs.

MONEY.COM: Now, in terms of the development of these
markets, I guess you've developed your model because
we've seen this type of growth before?

KIPPOLA: That's right. The model that we've been
using is the technology adoption life-cycle model,
which says that when revolutionary new technologies
are thrown out to a marketplace, there's a set of
early adopters and then there's a lull or a chasm
between the early adopters and the mainstream market.
And then there are various stages of adopters in the
mainstream market. There are a lot of technologies, of
course, that do very well in a early market but die
off in a chasm and never make it to the mainstream.

MONEY.COM: And, just for an example, is Intel
(OTC:INTC) a gorilla?

KIPPOLA: Intel is a gorilla, Microsoft's (OTC:MSFT) a
gorilla, Cisco's (OTC: CSCO) a gorilla. I think those
three companies are probably the most dominant
gorillas in the computing space today. But there are a
lot of other gorillas that are not in enabling
technologies like those three are, but are in software
application areas. SAP (OTC:SAPE), which owns about
35% of the back-office software market, is a gorilla.

MONEY.COM: Some of the other terms that you use in
the book: companies can be chimps, they can be kings,
they can be monkeys. It strikes me that chimps,
monkeys and gorillas are pretty similar: What are the
subtle differences between them in terms of the
companies?

KIPPOLA: Well, first of all, chimps are companies
that play in the same arena as gorillas but did not
get picked to be a gorilla. Monkeys tend to come in
later in a market and they clone a gorilla's
architecture. So, for instance, AMD (NYSE: AMD) and
Cyrix (NYSE: NSM) in microprocessors have really
cloned the Intel microprocessor and, therefore, they
are monkeys. Whereas Motorola has a completely
different architecture and we refer to them as a
chimp.

What distinguishes gorilla/chimp/monkey markets, from
what we call king/prince/serf markets is in
king/prince/serf markets, no one owns the
architecture. So, for instance, in the modem
marketplace, nobody owns the architecture for modem
protocols; that's set by industry standards. And,
therefore, nobody can gain the strength that a gorilla
gains in its marketplace because they don't have
proprietary architectures with high switching costs.
The PC marketplace is a marketplace that is panning
out to be a king/prince/serf marketplace, where we
have market leaders, like Compaq, which we would call
kings, but they don't have near the market share that
a gorilla has in its marketplace.

MONEY.COM: Okay. And talking high switching costs, I
guess that would be a real key in establishing
yourself as a gorilla. It costs too much for people
to switch from your products once they've already got
them? Is that the idea?

KIPPOLA: That's correct. So, for instance, we've a
lot of Fortune Global 1000 companies installing SAP
today and in the last few years. Installing SAP is a
long process, can take many years for some companies.
And not only does it take a long time, but it takes a
lot of money to implement it. To rip SAP out and put a
competing vendor's product in is just too prohibitive.
So most companies won't even think of doing it, even
if they don't like the vendor's software that they've
installed.

MONEY.COM: And Intel, then, would be something like
the high cost of coming up with a product that's
better than theirs?

KIPPOLA: Well, Intel fits the model, yes. But
because they have monkeys in their marketplace, those
monkeys -- AMD and Cyrix -- can get your business the
next time you jump to a new PC. However, it's unlikely
that if you already have a Windows-based machine that
you're going to jump to a Motorola-based machine or
some other microprocessor that's incompatible with the
one you already have, because you already have too
much sunk costs in the applications, in the data, and
your current machine.

Tomorrow: How to make the most of the gorilla game in
your investing.

ht
david



To: Sergio H who wrote (5819)6/11/1998 11:25:00 PM
From: Amigo Mike  Read Replies (2) | Respond to of 29382
 
Re: Antex Biologics (ANTX)

My visit to the annual shareholders meeting was very pleasant. I arrived about 1/2 hour early and ran into Scott and Rip (long time Antex shareholders) outside the hotel. We greeted each other and chatted a few minutes. Then went into the hotel to the meeting room.

Upon entry into the room, I was warmly greeted by name by Dr Esposito .... then Terry ..... then Don Stark (my favorite director). After exchanging a few pleasantries, the meeting began. There were around 8-10 other shareholders at the meeting. Dr Esposito went through the vote items. Then gave his address which is now available on the Antex website for all shareholders.

After the message to shareholders, the vote was taken. Shareholders overwhelmingly approved are three items. I must say that I was very surprised the vote was 8 to 1 in favor of the reverse split ..... especially in light of the range given rather than a specific split ratio. I thought for sure that it would be a close vote since many feel reverse split are detrimental to their pocketbooks. I get a sense that Antex shareholders are united on the reverse issue (which is very positive) and appear to trust management to do the right thing. This is a very positive thing. It gives me the sense that there will be much less downward pressure when a reverse is affected by management.

We discussed briefly (as we had previously) the desired ratio for the reverse. Clearly, management wants the reverse to be 1 for 4 to 1 for 6. Anything more than that will be very undesirable. They have already made all the necessary arrangements for the reverse and consulted financial types about the float issue after a reverse is affected. Bottom line ....... I feel much better about the reverse split knowing other shareholders voted 8 to 1 FOR the reverse.

We had a brief discussion regarding the Blair warrants. Generally, these will not likely be exercised until near expiration .... which would be March 2000. Bottom line here is there is less risk for Blair by exercising later after Antex has matured further and is trading on a national exchange.

Besides the reverse issue, the formation of AntexPharma was the next highlight of the meeting. We have heard for sometime that Antex technologies lent themselves to therapeutic and diagnostic applications. We now have a subsidiary dedicated to developing this area. Antex is currently seeking around 4 more scientists to get things moving faster. AntexPharma ..... I believe ..... will start off with hospital type infections ..... i.e. Staphylococcus and a few others that have been more and more resistant to antibiotics. Antex's technology more accurately mimics the body's reaction to infection thereby affording Antex a way to produce bacteria that would be more like the real thing rather than a lab culture. Big benefit here. What kind of market do anti-infectives represent for AntexPharma ????? According to Antex ..... the current marketplace is $26 Billion. The market for human vaccines is expected to be around $7.3 Billion by 2001. AntexPharma is a new exciting opportunity for our little company. It has been a long time coming .... but IMO ...... the first clinical trials have validated the technology's worth ..... and now Antex is going to put the technology to broader use developing therapeutic applications.

Clinicals ...... Campy is now the number one cause of food borne illness now....... outpacing salmonella. Dr Esposito expects the final report on Phase II campy during the third qtr. At that time, a determination will be made on whether to enter Phase III or adjust the adjuvant and dosages in another quick Phase II. The Phase III trial preparations have already been discussed. Thailand, I believe, has been selected as a likely location for real life field testing of the campy vaccine. Antex will be receiving some milestone $$$ from SKB upon completion of Phase II. Next is H Pylori. Phase I so far has been favorable for Antex. It is estimated that H Pylori infects 2/3 of the world's population. Causes the majority of peptic and gastric ulcers ...... and increasingly ..... linked to STOMACH CANCER. The Antex vaccine will basically search and destroy .... then protect against future infection. Phase I H Influenzae (nontypeable) for ear infections has been completed for adults with favorable results. Another Phase I is been started for testing on children. I wish to point out here that this vaccine ..... combined with the start of Moraxella trials (4th qtr) will potentially represent big $$$$$$ for Antex. Think about the vaccination of every newborne child in the civilized world. Milestone money later this year ($500K) from Pasteur due based on this vaccine. I had expected C Trachomatis for sexually transmitted diseases to be the next candidate to enter the clinical stage. But it appears that moraxella has jumped ahead. I feel that the chlamydia may be developed by AntexPharma.

Antex currently has 44 allowed or issued patents worldwide on its proprietary technologies and processes.

After the meeting, I and a few other shareholders toured the facilities at Antex and were introduced to quite a few of Antex's scientists ..... including one sent by SKB to work with Antex. The facilities will double in size later this year as Antex expands. Antex has 5 labs and several other multipurpose lab rooms. The offices are very nice and tasteful. Incidentally, the offices are not adorned with lavish appointments but rather melamine type modular desks. Very nice.

In my humble opinion, Antex, with alliances with SKB and Pasteur, research and development in conjunction with the National Institutes of Health and the US Department of Defense ..... proprietary wholly owned technology, clinicals in progress on 4 vaccine candidates (paid by alliance partners), 4 more in preclinicals, new subsidiary dedicated solely to therapeutics starting with hospital - acquired infections and 44 patents ......... IS FAR, FAR UNDERVALUED. The investment banking model provided by Jay Abella at Westergaard values Antex around $3 right now. I agree ...... $3 is a minimum value in my book as that would give Antex a market cap of only $66 million today. To see Antex trade in the .68- .84 range is an OUTRAGE to say the least. Once Antex reverses and achieves an AMEX or NASDAQ listing ...... I expect the market to correct this severe undervaluation and move Antex to higher levels. Antex will continue to have my support and I will continue as a shareholder and owner for the forseeable future.

Long and still accumulating,
Amigo Mike

PS Incidentally ..... Antex would rather SKB ..... NOT exercise their option for $1 million in October of this year. They'd rather SKB pay more to purchase shares in Antex. =)